Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

書誌詳細
主要な著者:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
フォーマット:	論文
言語:	English
出版事項:	Wiley 2023-08-01
シリーズ:	ESC Heart Failure
主題:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
オンライン･アクセス:	https://doi.org/10.1002/ehf2.14304

類似資料

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
著者:: Douglas B. Johnson, 等
出版事項: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
著者:: Federica Costa, 等
出版事項: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
著者:: Laura I. Yousif, 等
出版事項: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
著者:: Vickram A S, 等
出版事項: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
著者:: Ruby Dhar, 等
出版事項: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
著者:: Kazuhiko Hashimoto, 等
出版事項: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
著者:: Jing Huang, 等
出版事項: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
著者:: Juwon Lee, 等
出版事項: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
著者:: Ruiting Li, 等
出版事項: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
著者:: Sai Mummareddy, 等
出版事項: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
著者:: Tianrui Yang, 等
出版事項: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
著者:: Jan Willem Kleinovink, 等
出版事項: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
著者:: Sebastian Marwitz, 等
出版事項: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
著者:: Yavar Shiravand, 等
出版事項: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
著者:: YU Lin, 等
出版事項: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
著者:: Ahmed M. Basudan
出版事項: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
著者:: Gabriel Surdacki, 等
出版事項: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
著者:: Andreas von Knethen, 等
出版事項: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
著者:: Alberto Bongiovanni, 等
出版事項: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
著者:: Ya Xu, 等
出版事項: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
著者:: Edyta Zyla, 等
出版事項: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
著者:: Emily Hensler, 等
出版事項: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
著者:: Mihnea Dragomir, 等
出版事項: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
著者:: Maria Georganaki, 等
出版事項: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
著者:: William L. Redmond, 等
出版事項: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
著者:: Reid P. Bissonnette, 等
出版事項: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
著者:: Ji Won Han, 等
出版事項: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
著者:: Kübra KAHVECİ, 等
出版事項: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
著者:: Zachary S. Buchwald, 等
出版事項: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
著者:: Amjad Zafar, 等
出版事項: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
著者:: Jiaxin Zhou, 等
出版事項: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
著者:: Adel Naimi, 等
出版事項: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
著者:: Zhanjun Guo, 等
出版事項: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
著者:: Troy A McEachron, 等
出版事項: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
著者:: Deniz Can Guven, 等
出版事項: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
著者:: Kuti Baruch, 等
出版事項: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
著者:: Leona Raskova Kafkova, 等
出版事項: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
著者:: Shuai Wang, 等
出版事項: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
著者:: Silvia Pesce, 等
出版事項: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
著者:: Boris Klebansky, 等
出版事項: (2024-05-01)